Travere Therapeutics (TVTX) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free TVTX Stock Alerts $5.48 +0.09 (+1.67%) (As of 10:20 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineTravere Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($1.80) Per Share (NASDAQ:TVTX)marketbeat.com - April 26 at 10:38 AMBuy Rating Affirmed for Travere Therapeutics Following Filspari’s European Approval and Promising US Prospectsmarkets.businessinsider.com - April 26 at 7:50 AMFY2028 EPS Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX) Cut by Analystamericanbankingnews.com - April 26 at 3:50 AMBuy Rating Affirmed for Travere Therapeutics on EU Approval and Promising Revenue Projectionsmarkets.businessinsider.com - April 25 at 7:49 PMTravere Therapeutics, Inc. (NASDAQ:TVTX) Forecasted to Post FY2028 Earnings of $4.29 Per Sharemarketbeat.com - April 25 at 9:13 AMTravere Therapeutics (NASDAQ:TVTX) Price Target Increased to $19.00 by Analysts at HC Wainwrightamericanbankingnews.com - April 25 at 5:26 AMFILSPARI’s European Approval and Market Potential Bolster Buy Rating for Travere Therapeuticsmarkets.businessinsider.com - April 24 at 8:48 PMHC Wainwright Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $19.00marketbeat.com - April 24 at 3:53 PMTravere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathyglobenewswire.com - April 24 at 7:05 AMCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathyprnewswire.com - April 24 at 3:00 AMTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Recommendation of "Moderate Buy" from Analystsamericanbankingnews.com - April 24 at 2:50 AMVontobel Holding Ltd. Purchases Shares of 287,423 Travere Therapeutics, Inc. (NASDAQ:TVTX)marketbeat.com - April 19 at 5:37 AMTravere Therapeutics' (TVTX) Outperform Rating Reaffirmed at Wedbushamericanbankingnews.com - April 18 at 5:30 AMTravere Therapeutics (NASDAQ:TVTX) Earns "Outperform" Rating from Wedbushmarketbeat.com - April 17 at 3:51 PMTravere Therapeutics CFO sells shares to cover tax obligationsinvesting.com - April 14 at 12:58 AMVanguard Group Inc. Acquires 460,176 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)marketbeat.com - April 10 at 4:00 AMStock market today: Stocks slide after Fedspeak as oil surges, March jobs report on decknz.finance.yahoo.com - April 4 at 8:02 PMTravere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians Internationalglobenewswire.com - April 4 at 4:30 PMTravere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Associationglobenewswire.com - April 3 at 4:30 PMTravere Therapeutics (NASDAQ:TVTX) Trading Down 6%marketbeat.com - April 1 at 4:50 PMTravere Therapeutics (NASDAQ:TVTX) Shares Gap Down to $7.57marketbeat.com - March 27 at 12:23 PMTravere Therapeutics (NASDAQ:TVTX) Receives "Neutral" Rating from Guggenheimmarketbeat.com - March 27 at 8:18 AMTravere Therapeutics (NASDAQ:TVTX) Trading 7.5% Higher marketbeat.com - March 21 at 5:42 PMTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - March 13 at 5:00 PMBuy Rating Affirmed for Travere Therapeutics on Strong FILSPARI Data and Favorable Regulatory Outlookmarkets.businessinsider.com - March 13 at 2:22 PMPeeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insightsmarkets.businessinsider.com - March 13 at 2:22 PMTravere Therapeutics (NASDAQ:TVTX) Trading 6.1% Higher marketbeat.com - March 13 at 1:51 PMJacobs Levy Equity Management Inc. Boosts Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)marketbeat.com - March 12 at 8:39 AMTravere Therapeutics Submits SNDA Seeking Full Approval Of Filspari In IgA Nephropathymarkets.businessinsider.com - March 11 at 7:50 AMTravere Therapeutics Submits SNDA Seeking Full Approval Of Filspari In IgA Nephropathymarkets.businessinsider.com - March 11 at 7:50 AMTravere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)globenewswire.com - March 11 at 7:05 AMSchonfeld Strategic Advisors LLC Has $4.69 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)marketbeat.com - March 5 at 9:30 AMTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Recommendation of "Moderate Buy" by Analystsmarketbeat.com - March 5 at 1:34 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (MRNA) and Travere Therapeutics (TVTX)markets.businessinsider.com - February 28 at 4:43 AMTravere Therapeutics to Present at Upcoming Investor Conferencesglobenewswire.com - February 26 at 4:30 PMBuy Rating Affirmed: Expanding Market Potential for Travere Therapeutics’ Sparsentanmarkets.businessinsider.com - February 23 at 3:50 PMTravere drug for rare kidney condition recommended for EU approvalmsn.com - February 23 at 10:50 AMTravere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathyglobenewswire.com - February 23 at 7:05 AMState of New Jersey Common Pension Fund D Takes Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)marketbeat.com - February 22 at 4:48 AMRafferty Asset Management LLC Reduces Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)marketbeat.com - February 21 at 6:43 AMTVTX Mar 2024 30.000 callfinance.yahoo.com - February 18 at 5:14 AMWells Fargo & Company Boosts Travere Therapeutics (NASDAQ:TVTX) Price Target to $9.00marketbeat.com - February 16 at 2:46 PMTravere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - February 16 at 2:00 PMDeep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)markets.businessinsider.com - February 16 at 2:00 PMCanada Pension Plan Investment Board Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)marketbeat.com - February 16 at 6:26 AMAnalysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Travere Therapeutics (TVTX) and Grifols SA (GRFS)markets.businessinsider.com - February 16 at 3:59 AMTravere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimatesmsn.com - February 15 at 8:04 PMTravere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsfinance.yahoo.com - February 15 at 8:04 PMTravere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - February 15 at 4:01 PMTravere Therapeutics Q4 2023 Earnings Previewmsn.com - February 15 at 12:03 AM Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow. Click here for your free guide TVTX Media Mentions By Week TVTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼0.710.33▲Average Medical News Sentiment TVTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼133▲TVTX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Entrada Therapeutics News Today Theravance Biopharma News Today Shattuck Labs News Today Avid Bioservices News Today Acelyrin News Today Lexicon Pharmaceuticals News Today IGM Biosciences News Today Adlai Nortye News Today Fulcrum Therapeutics News Today Larimar Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss RatingsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
